NextCure
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, NextCure sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
NextCure: 7 sponsored US clinical trials, 2 recruiting.
NextCure sponsors 7 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced or Metastatic Solid Tumors, with 2 trials.
Upper-quartile sponsor footprint
NextCure sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
7 total, page 1 of 1
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
NCT06792552
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
NCT06774963
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors
NCT05572684
A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
NCT05787496
A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors
NCT04875806
A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors
NCT04408599
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
NCT03665285
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
What is open in the NextCure pipeline
2 recruiting of 7 indexed (29% open); 1 completed (14%).
Phase mix: 0 late (III/IV) vs 7 early (I/II) (early-phase heavy).
Top condition: Advanced or Metastatic Solid Tumors (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
NextCure: open-pipeline peers nationwide
Peers matched on 7 registered trials and 29% open enrollment, not the therapeutic-area sidebar.
NextCure sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 trials (± recruiting share)
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors near 29% open enrollment (± trial volume)
- Alabama Physical Therapy & Acupuncture · 29% recruiting · 14 trials
- AlloSource · 29% recruiting · 7 trials
- Alnylam Pharmaceuticals · 29% recruiting · 49 trials
- Annovis Bio · 29% recruiting · 7 trials
Related
What to do with this NextCure page
7 registered trials is a research-attention snapshot, not an endorsement of NextCure or any single study.
- 2 of NextCure's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Advanced or Metastatic Solid Tumors is the condition NextCure studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced or Metastatic Solid Tumors trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
NextCure pipeline card: 7 registered trials from official public datasets.Report a data error.